$1.55+1.19 (+323.14%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Scinai Immunotherapeutics (SCNI) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue history is too short to read a growth trend, net margin −633.6%. Worth your attention in FY25: Share count (+1554.2%) and Capex step-up ($24.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($K)▲99.2%
1,311.0
FY21→FY25CAGR —
Net income ($K)—
−8,307.0
FY21→FY25CAGR —
Free cash flow ($K)▲4.6%
−6,055.0
capex stepped upCAGR —
Diluted EPS—
0.00
no value for 2 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+1554.2%
0.6bn → 9.3bn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$24.0K
▲100% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
-634¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -633.6% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 7.11, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 1,311.0 | 658.0 | 0.0 | 0.0 | 0.0 | ▲99.2% | — |
Cost of revenue | — | 3,963.0 | 1,238.0 | 0.0 | 0.0 | 0.0 | ▲220.1% | — |
Gross profit | — | −2,652.0 | −580.0 | 0.0 | 0.0 | 0.0 | ▼357.2% | — |
Research & development | 6,597.0 | 2,369.0 | 5,532.0 | 5,210.0 | 5,765.0 | 3,249.0 | ▼57.2% | −7.6% |
Selling, general & admin | 5,035.0 | 2,521.0 | 2,526.0 | 4,505.0 | 5,296.0 | 7,625.0 | ▼0.2% | −24.2% |
Total operating expenses | 11,632.0 | 4,890.0 | 8,058.0 | 9,715.0 | 11,061.0 | 10,874.0 | ▼39.3% | −18.1% |
Operating incomefeeds ROC rank | −11,632.0 | −7,542.0 | −8,638.0 | −9,706.0 | −11,061.0 | −10,874.0 | ▲12.7% | — |
Other income, net | 4,796.0 | −765.0 | 13,434.0 | 3,215.0 | 5,265.0 | 2,668.0 | — | — |
Pretax income | −6,836.0 | −8,307.0 | 4,796.0 | −6,491.0 | −5,796.0 | −8,206.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −6,836.0 | −8,307.0 | 4,796.0 | −6,500.0 | −5,796.0 | −8,206.0 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | 0.00 | 0.00 | — | — | −0.02b | — | — |
Diluted shares (bn) | — | 9.34 | 3.23 | — | — | 0.56 | ▲189.6% | — |
| Margins | ||||||||
Gross margin0th pct in Healthcare | — | −202.3% | −88.1% | — | — | — | ▼114.1pp | — |
Operating margin | — | −575.3% | −1312.8% | — | — | — | ▲737.5pp | — |
Net margin13th pct in Healthcare | — | −633.6% | 728.9% | — | — | — | ▼1362.5pp | — |
† TTM = trailing four quarters through 2023-03-31.b Basic EPS. The company's diluted figure is not in our data feed for this period; its reported basic EPS agrees with net income to common shareholders over basic shares within 2%, so it is shown instead.
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-04-01 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Scinai Immunotherapeutics' revenue last fiscal year?
Scinai Immunotherapeutics reported revenue of $1,311.0K in fiscal 2025, up 99.2% from fiscal 2024.
What was Scinai Immunotherapeutics' net income?
Scinai Immunotherapeutics reported net income of −$8,307.0K in fiscal 2025, a net margin of −633.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

